Search
Chondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceutical[A32063] Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.[A32066] … Chondroitin sulfate is composed of alternating 1,3-N-acetyl-β-d-galactosamine and 1,4-β-d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific
Mixtures: Blackmores Joint Formula with Glucosamine and ChondroitinCategories: Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-SteroidsDiabetic Neuropathies
go.drugbank.com/conditions/DBCOND0028190Drugs: Amitriptyline · Botulinum toxin type A · Citalopram · Cyanocobalamin · Desipramine · Lipoic acid +1 moreSynonyms: Neuropathy co-occurrent and due to diabetes mellitusVitamin B1 deficiency
go.drugbank.com/conditions/DBCOND0015755Synonyms: (Thiamine and niacin deficiency states) or (vitamin B1 deficiency)Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[L54748] Developed through a collaboration involving the Global Antibiotic Research and Development Partnership (GARDP), zoliflodacin received approval from the U.S. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalSipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Categories: Antineoplastic and Immunomodulating AgentsLovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigationalolder to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsAcetylcarnitine
go.drugbank.com/drugs/DB08842ApprovedInvestigationalIn human plasma and tissues, acetylcarnitine is the most predominant acylated ester of carnitine, which is an amino acid derivative that is made in the kidney, liver, and brain from lysine and methionine … Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsPixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnPixantrone is an aza-anthracenedione and DNA intercalator which inhibits topoisomerase II. … Patients refractory to treatment, or those who relapse, are discouraged from further anthracycline use due to cumulative cardiotoxicity.
Categories: Anthracyclines and Related Substances, Antineoplastic and Immunomodulating AgentsDeep vein thrombosis recurrent
go.drugbank.com/conditions/DBCOND0025031Synonyms: Acute embolism and thrombosis of unspecified deep veins of lower extremity